Skip to main content
Erschienen in: Journal of Cancer Survivorship 1/2012

01.03.2012

Breast and colorectal cancer survivors’ knowledge about their diagnosis and treatment

verfasst von: Mary Jo Nissen, Michaela L. Tsai, Anne H. Blaes, Karen K. Swenson

Erschienen in: Journal of Cancer Survivorship | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Aspects of a personal cancer history can have implications for future decisions regarding screening, diagnosis, and treatment. Clinicians must sometimes rely on patients’ self-report of their medical history. This study assessed knowledge of details of cancer diagnosis and treatment among breast and colorectal cancer survivors.

Methods

Written surveys were completed by 480 breast cancer survivors and 366 colorectal cancer survivors diagnosed between 1999 and 2008 at a large cancer center in the Minneapolis, MN, area (81% response rate). Responses were compared with cancer registry and medical records.

Results

Forty percent of breast cancer survivors and 65% of colorectal cancer survivors were unable to identify their stage of disease. Seven percent of breast cancer survivors and 21% of colorectal cancer survivors in whom regional nodes were examined did not know whether they had positive nodes. Accuracy of knowledge of estrogen and progesterone status among breast cancer survivors was 58% and 39%, respectively. Of breast cancer survivors treated with doxorubicin, 43% correctly identified it as a drug they had received. Their accuracy of identification of receipt of tamoxifen or specific aromatase inhibitors was >90%. Of colorectal cancer survivors treated with oxaliplatin, 52% correctly identified it as a drug they had received. Accuracy on many items decreased with patient age.

Conclusions

This study identifies several gaps in adult cancer survivors’ knowledge of details of their diagnosis and treatment that have implications for follow-up care.

Implications for cancer survivors

Provision of written treatment summaries to cancer survivors could help them obtain appropriate patient-centered long-term follow-up care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008.PubMedCrossRef Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25:3991–4008.PubMedCrossRef
3.
Zurück zum Zitat Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5:S38–46.PubMedCrossRef Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5:S38–46.PubMedCrossRef
4.
Zurück zum Zitat Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26:1051–7.PubMedCrossRef Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26:1051–7.PubMedCrossRef
5.
Zurück zum Zitat Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–35.PubMedCrossRef Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–35.PubMedCrossRef
6.
Zurück zum Zitat Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.PubMedCrossRef Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.PubMedCrossRef
7.
Zurück zum Zitat Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncology. 2009;91:4–15.CrossRef Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncology. 2009;91:4–15.CrossRef
8.
Zurück zum Zitat Mosen DM, Schmittdiel J, Hibbard J, Sabel D, Remmers C, Bellows J. Is patient activation associated with outcomes of care for adults with chronic conditions? J Ambulatory Care Manage. 2007;30:21–9.PubMed Mosen DM, Schmittdiel J, Hibbard J, Sabel D, Remmers C, Bellows J. Is patient activation associated with outcomes of care for adults with chronic conditions? J Ambulatory Care Manage. 2007;30:21–9.PubMed
9.
Zurück zum Zitat Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington: Institute of Medicine, National Academies Press; 2006. Hewitt M, Greenfield S, Stovall E, editors. From cancer patient to cancer survivor: lost in transition. Washington: Institute of Medicine, National Academies Press; 2006.
12.
Zurück zum Zitat Desai MM, Bruce ML, Desai RA, Druss BG. Validity of self-reported cancer history: a comparison of health interview data and cancer registry records. Am J Epidemiol. 2001;153:299–306.PubMedCrossRef Desai MM, Bruce ML, Desai RA, Druss BG. Validity of self-reported cancer history: a comparison of health interview data and cancer registry records. Am J Epidemiol. 2001;153:299–306.PubMedCrossRef
13.
Zurück zum Zitat Paganini-Hill A, Chao A. Accuracy of recall of hip fracture, heart attack, and cancer: a comparison of postal survey data and medical records. Am J Epidemiol. 1993;138:101–6.PubMed Paganini-Hill A, Chao A. Accuracy of recall of hip fracture, heart attack, and cancer: a comparison of postal survey data and medical records. Am J Epidemiol. 1993;138:101–6.PubMed
14.
Zurück zum Zitat Schrijvers CTM, Stronks K, van de Mheen DH, Coebergh JW, Mackenbach JP. Validation of cancer prevalence data from a postal survey by comparison with cancer registry records. Am J Epidemiol. 1994;139:408–14.PubMed Schrijvers CTM, Stronks K, van de Mheen DH, Coebergh JW, Mackenbach JP. Validation of cancer prevalence data from a postal survey by comparison with cancer registry records. Am J Epidemiol. 1994;139:408–14.PubMed
15.
Zurück zum Zitat Abraham L, Geller BM, Yankaskas BC, Bowles EJA, Karliner LS, Taplin SH, et al. Accuracy of self-reported breast cancer among women undergoing mammography. Breast Cancer Res Treat. 2009;118:583–92.PubMedCrossRef Abraham L, Geller BM, Yankaskas BC, Bowles EJA, Karliner LS, Taplin SH, et al. Accuracy of self-reported breast cancer among women undergoing mammography. Breast Cancer Res Treat. 2009;118:583–92.PubMedCrossRef
16.
Zurück zum Zitat Bergmann MM, Calle EE, Mervis CA, Miracle-McMahill HL, Thun MJ, Heath CW. Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol. 1998;147:556–62.PubMed Bergmann MM, Calle EE, Mervis CA, Miracle-McMahill HL, Thun MJ, Heath CW. Validity of self-reported cancers in a prospective cohort study in comparison with data from state cancer registries. Am J Epidemiol. 1998;147:556–62.PubMed
17.
Zurück zum Zitat Manjer J, Merlo J, Berglund G. Validity of self-reported information on cancer: determinants of under and over-reporting. Eur J Epidemiol. 2004;19:239–47.PubMedCrossRef Manjer J, Merlo J, Berglund G. Validity of self-reported information on cancer: determinants of under and over-reporting. Eur J Epidemiol. 2004;19:239–47.PubMedCrossRef
18.
Zurück zum Zitat Parikh-Patel A, Allen M, Wright WE, and the California Teachers Study Steering Committee. Validation of self-reported cancers in the California Teachers Study. Am J Epidemiol. 2003;157:539–45.PubMedCrossRef Parikh-Patel A, Allen M, Wright WE, and the California Teachers Study Steering Committee. Validation of self-reported cancers in the California Teachers Study. Am J Epidemiol. 2003;157:539–45.PubMedCrossRef
19.
Zurück zum Zitat Nord C, Mykletun A, Fossa SD. Cancer patients’ awareness about their diagnosis: a population-based study. J Public Health Med. 2003;25:313–7.PubMedCrossRef Nord C, Mykletun A, Fossa SD. Cancer patients’ awareness about their diagnosis: a population-based study. J Public Health Med. 2003;25:313–7.PubMedCrossRef
20.
Zurück zum Zitat Kadan-Lottick NS, Robison LL, Gurney JG, Neglia JP, Yasui Y, Hayashi R, et al. Childhood cancer survivors’ knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA. 2002;287:1832–9.PubMedCrossRef Kadan-Lottick NS, Robison LL, Gurney JG, Neglia JP, Yasui Y, Hayashi R, et al. Childhood cancer survivors’ knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA. 2002;287:1832–9.PubMedCrossRef
21.
Zurück zum Zitat Bashore L. Childhood and adolescent cancer survivors’ knowledge of their disease and effects of treatment. J Ped Oncol Nurs. 2004;21:98–102.CrossRef Bashore L. Childhood and adolescent cancer survivors’ knowledge of their disease and effects of treatment. J Ped Oncol Nurs. 2004;21:98–102.CrossRef
22.
Zurück zum Zitat Byrne J, Lewis MES, Halamek L, Connelly RR, Mulvihill JJ. Childhood cancer survivors’ knowledge of their diagnosis and treatment. Ann Intern Med. 1989;110:400–3.PubMed Byrne J, Lewis MES, Halamek L, Connelly RR, Mulvihill JJ. Childhood cancer survivors’ knowledge of their diagnosis and treatment. Ann Intern Med. 1989;110:400–3.PubMed
23.
Zurück zum Zitat Royak-Schaler R, Gardner LD, Shardell M, Zhan M, Passmore SR, Gadalla SM, et al. Evidence-based care for breast cancer survivors: communicating the Institute of Medicine guidelines in medical practice. Patient Educ Couns. 2009;77:413–20.PubMedCrossRef Royak-Schaler R, Gardner LD, Shardell M, Zhan M, Passmore SR, Gadalla SM, et al. Evidence-based care for breast cancer survivors: communicating the Institute of Medicine guidelines in medical practice. Patient Educ Couns. 2009;77:413–20.PubMedCrossRef
24.
Zurück zum Zitat Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94:835–44.PubMedCrossRef Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94:835–44.PubMedCrossRef
25.
Zurück zum Zitat Cress RD, Zaslavsky AM, West DW, Wolf RE, Felter MC, Ayanian JZ. Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care. 2003;41:1006–12.PubMedCrossRef Cress RD, Zaslavsky AM, West DW, Wolf RE, Felter MC, Ayanian JZ. Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care. 2003;41:1006–12.PubMedCrossRef
Metadaten
Titel
Breast and colorectal cancer survivors’ knowledge about their diagnosis and treatment
verfasst von
Mary Jo Nissen
Michaela L. Tsai
Anne H. Blaes
Karen K. Swenson
Publikationsdatum
01.03.2012
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 1/2012
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-011-0189-3

Weitere Artikel der Ausgabe 1/2012

Journal of Cancer Survivorship 1/2012 Zur Ausgabe

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.